Bluejay Diagnostics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Bluejay Diagnostics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $249.0K | Mar 28, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $48.9K | Mar 28, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.85M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($7.72M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($9.95M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($9.30M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($3.49M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($1.16M) | Mar 10, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.95M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($7.17M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($10.31M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($9.32M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($3.23M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($1.20M) | Mar 10, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.05M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $3.47M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $5.71M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.15M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.15M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $527.3K | Mar 10, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $283.4K | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | $451.4K | Mar 28, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.05M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($7.82M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($8.31M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.74M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($4.37M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($508.7K) | Mar 10, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $173.7K | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $306.8K | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $704.2K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.20M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $23.9K | Mar 20, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.12M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $6.66M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $4.87M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.52M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $21.02M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $1.52M | Mar 10, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $927.9K | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $1.97M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.98M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $637.2K | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $1.85M | Mar 10, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.98M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $5.73M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $2.89M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $11.54M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $20.38M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($4.21M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2019 | ($2.93M) | Mar 10, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.52M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($34.67M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($26.95M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($17.00M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($7.69M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($4.21M) | Mar 10, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.16M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $4.30M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $2.21M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $10.11M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $19.05M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $912.4K | Mar 10, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (15) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (456) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | (3,631) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (9) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 20, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (15) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (456) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | (3,631) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (9) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 20, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 604,534 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 138,503 | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 3,098 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 1.01M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 20.11M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | 3.15M | Mar 10, 2022 |